Description: Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company was founded by John Kollins on June 21, 2016 and is headquartered in San Francisco, CA.
Home Page: www.satsumarx.com
STSA Technical Analysis
400 Oyster Point Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 410 3200
Officers
| Name | Title |
|---|---|
| Mr. John A. Kollins MBA | Pres, CEO & Director |
| Mr. Thomas P. O'Neil | Chief Financial Officer |
| Dr. Detlef F. Albrecht | Chief Medical Officer |
| Mr. Mic Iwashima | VP & Head of Operations |
| Mr. Robert Schultz | Sr. VP & Head of Chemistry, Manufacturing and Controls |
| Dr. Shannon Strom Ph.D. | VP & Head of Regulatory Affairs |
| Mr. Robert M. Janosky | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Regional Banks |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4202 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-09-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 25 |